AF in Cancer Patients: A Different Need for Anticoagulation?
Cancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology...
Guardado en:
Autores principales: | Ana Pardo Sanz, José Luis Zamorano Gómez |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d917cf8638154e9aabb6116bbb7aaa9d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Direct Oral Anticoagulants Concentration Testing in Clinical Practice for High-Risk Patients with AF
por: K Pukite, et al.
Publicado: (2020) -
Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
por: Maki Komiyama, et al.
Publicado: (2020) -
High-resolution Mapping in Patients with Persistent AF
por: Marius Andronache, et al.
Publicado: (2019) -
Atrial Fibrosis: Translational Considerations for the Management of AF Patients
por: Stylianos Tzeis, et al.
Publicado: (2019) -
Predictors of Recurrence of AF in Patients After Radiofrequency Ablation
por: Iskren Garvanski, et al.
Publicado: (2019)